Home >> Tag Archives: Wako Diagnostics—

Tag Archives: Wako Diagnostics—

Microfluidic-based clinical immunoanalyzer, 7/14

July 2014—Wako Life Sciences’ µTasWako i30 is available for the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) tests, which are intended for in vitro diagnostic use to help in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma in conjunction with other laboratory findings, imaging studies, and clinical assessment.

Read More »

Immunoanalyzer licensed for clinical use in Canada, 10/13

Wako Diagnostics was issued three class III medical device licenses by Health Canada to market the uTAS-Wako i30 instrument with the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma.

Read More »
X